Damien Parlier

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick et al. · Annals of Oncology · 2022 · 52 citations · Full text

Medicine, Immunology, Oncology +14

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick et al. · Journal of Clinical Oncology · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

Evandro de Azambuja, Elisa Agostinetto, Marion Procter et al. · ESMO Open · 2023 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16